Rainbow Biotech completes nearly 100 million yuan Pre-A+ round of financing

Recently, Shenzhen Hongxin Biotechnology Co., Ltd. announced the completion of nearly 100 million yuan in Pre-A+ round financing. This round of financing was led by IDG Capital, with follow-up investments from Hillhouse Ventures and Yuansheng Ventures, and existing investor Hengye Science and Technology Investment continued to increase its investment. This round of financing will be used for the IND application and IIT clinical research of the core product HN2301.